RNXT Stock — RenovoRx Inc.: Cash, EV, Pipeline

Share price

$1.69

Market cap

$76.3M

Cash

$9.5M

Enterprise value

$66.8M

Balance sheet

Cash	$9.5M
Debt	$0.0M
Net cash	$9.5M
Enterprise value	$66.8M
Basic shares	45.1M shares
Fully diluted shares	53.8M shares
Fully diluted market cap	$90.9M
Cash per share	$0.21

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RNXT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Gemcitabine	Phase 3	Locally Advanced Pancreatic Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IAG

Phase 3 · Active Modality: drug-device combination

Aliases intra-arterial gemcitabine

Indications

Locally advanced pancreatic cancer (Phase 3)
Bile duct cancer (Stage not disclosed)

Status note Intra-arterial gemcitabine delivered via RenovoCath (TAMP platform) in ongoing Phase III TIGeR-PaC trial for LAPC. Orphan Drug Designation for pancreatic cancer and bile duct cancer. New IIT in cholangiocarcinoma began Q2 2026.

Oxaliplatin (TAMP)

Stage not disclosed · Active Modality: drug-device combination

Indications

Pancreatic cancer (Stage not disclosed)

Status note Oxaliplatin delivered via RenovoCath under TAMP platform; Orphan Drug Designation granted Q2 2026 for pancreatic cancer.

RenovoCath

Approved · Active Modality: medical device

Indications

Vessel occlusion (device indication) (Approved)

Status note FDA-cleared for temporary vessel occlusion (arteriography, preoperative occlusion, chemotherapeutic drug infusion). Actively commercialized as standalone device.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Gemcitabine
Lead indication	Locally Advanced Pancreatic Cancer
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03257033	Phase 3	Recruiting	Sponsor	RenovoRx	—	Locally Advanced Pancreatic Cancer	—
NCT06805461	Not disclosed	Recruiting	Sponsor	RenovoRx	—	Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for RenovoRx on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

RNXT — RenovoRx Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials